AbbVie uncoupling costs Reata $330M in cold, hard cash
AbbVie, which in the process of acquiring Allergan for $63 billion, is relinquishing its license to a slate of Reata Pharmaceuticals experimental drugs, primarily …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
